Key facts
- Porosome Therapeutics’s last known valuation is $8.9M (Mar 2026).
- It has raised $3.9M across 1 recorded rounds; the latest was Seed Round ($3.6M) in Sep 2023.
- Notable investors include Private Ventures Group.
- Porosome Therapeutics has filed 3 Form Ds with the SEC since 2023, most recently Jun 2025 ($2.5M sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Porosome Therapeutics
Funding rounds
1 roundsAbout Porosome Therapeutics
Developer of a drug development platform designed to address diseases caused by secretory defects, including Alzheimer's, cystic fibrosis, and diabetes. The company's platform identifies small molecules for treating diseases and specializes in the development and delivery of next-generation antiviral therapeutics, enabling healthcare professionals to access affordable drugs and treatments.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 2
- Website
- porosome.com/
- Ownership
- Privately Held (backing)
Porosome Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Porosome Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Porosome Therapeutics in its N-PORT filings yet. We sweep new filings monthly.